COVID-specific T's may offset therapeutically endangered B's Comment

In this issue of Blood, Liebers et al(1) and Enssle et al(2) address the gap in knowledge on vaccine-induced T-cell immune responses in patients with lym-phoma or myeloma whose B-cell immunity is often therapeutically depleted.

Automated summary

The studies by Liebers et al and Enssle et al address the lack of knowledge regarding vaccine-induced T-cell immune responses in patients with lymphoma or myeloma who have depleted B-cell immunity.